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Cleaning validation, a requirement of the current Good Manufacturing Practices (cGMP) for Drugs, 
consists of documented evidence that cleaning procedures are capable of removing residues to 
predetermined acceptance levels. This report describes a strategy for the selection of the worst case product 
for the production of lyophilized reagents (LRs) for labeling with 99mTc from the Instituto de Pesquisas 
Energéticas e Nucleares (IPEN-CNEN/São Paulo). The strategy is based on the calculation of a “worst 
case index” that incorporates information about drug solubility, cleaning difficulty, and occupancy rate in 
the production line. It allowed a reduction in the required number of validations considering the possible 
manufacturing flow of a given product and the subsequent flow, thus facilitating the process by reducing 
operation time and cost. The products identified as “worst case” were LRs PUL-TEC and MIBI-TEC. 
Uniterms: Radiopharmaceuticals/production. Drugs/manufacturing/cleaning validation. Lyophilized 
reagents.
A validação de limpeza é uma exigência dos atuais regulamentos de Boas Práticas de Fabricação de 
Medicamentos (BPF) e consiste na evidência documentada, que demonstra que os procedimentos de 
limpeza removem os resíduos em níveis de aceitação pré-determinados. Este estudo apresenta uma 
estratégia para escolha do produto “pior caso” da linha de produção de reagentes liofilizados para marcação 
com 99mTc do Instituto de Pesquisas Energéticas e Nucleares (IPEN-CNEN/São Paulo). A estratégia baseia-
se no cálculo de um índice denominado “índice para pior caso,” que utiliza informações de solubilidade 
dos fármacos, dificuldade de limpeza dos equipamentos e ocupação dos produtos na linha de produção. 
A estratégia adotada proporcionou a diminuição no número de validações necessárias, considerando-se 
as possibilidades de sequências de fabricação de um determinado produto e do produto subsequente, 
possibilitando a simplificação do processo e redução no tempo e nos custos das atividades envolvidas. 
Os produtos indicados como pior caso foram os reagentes liofilizados (RL) PUL-TEC e MIBI-TEC.
Unitermos: Radiofármacos/produção. Medicamentos/fabricação/validação de limpeza. Reagentes 
liofilizados.
INTRODUCTION
Radiopharmaceuticals are defined as pharmaceutical 
preparations with diagnostic or therapeutic purposes, 
which when ready for use, contain one or more 
radionuclides (Brasil, 2009) and can be classified into 
four categories (World Health Organization, 1997): ready-
to-use radioactive products, radionuclide generators, 
non-radioactive components [“kits,” lyophilized 
reagents (LR)] for the preparation of labeled compounds 
with a radioactive component (usually the eluate from 
a radionuclide generator), and precursors used for 
radiolabeling other substances (e.g., samples from 
patients) before administration.
Medicine manufacturers must assure that all 
applicable and necessary actions during the manufacturing 
are implemented, ensuring that their products comply 
with the required quality standard so that they can be 
L. V. F. M. Porto, N. T. O. Fukumori, M. M. N. Matsuda106
put to their intended use. Therefore, the validation of the 
manufacturing process and all related activities, including 
equipment cleaning, ensures that safe and effective 
products are obtained (Brasil, 2010a).
Cleaning validation ensures that cleaning equipment 
procedures effectively remove existing residues 
(manufactured product residues, degradation products, 
conservatives, excipients, and/or cleaning agents) to 
a predetermined acceptance level. Thus, it is possible 
to guarantee that after the cleaning is performed, the 
next manufactured product will not contain substances 
from the previous process, i.e., there is no cross-
contamination (Brasil, 2010a; Waghmare et al., 2013). 
Cross-contamination control plays an important role in 
maintaining the product quality (Pawar et al., 2011).
The validation of every cleaning process used in 
the pharmaceutical industry would be a slow procedure, 
with high cost and delayed results. If a pharmaceutical 
industry produces n products, the number of possibilities 
for validating the cleaning equipment will be n!/(n − 2)!, 
where n! is the factorial number given by n(n − 1)(n − 2)… 
(3)(2)(1). Therefore, if an industry produces five products, 
the number of possible cleaning processes will be 120 
(Alencar et al., 2006b).
According to the International Conference on 
Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use (ICH) Q7A, if various 
active pharmaceutical ingredients or intermediates are 
manufactured in the same equipment and if the equipment 
is cleaned by the same process, it is acceptable to choose 
only one substance for cleaning validation. This selection, 
called worst case selection, should be based on the 
solubility and difficulty of cleaning, in addition to the 
calculation of maximum residue limits based on strength, 
toxicity, and stability (Food and Drug Administration, 
2001). The same criterion is considered valid by the World 
Health Organization; there is no need for the individual 
validation of cleaning processes and the study of the worst 
case is acceptable, as long as the selected substance is that 
presenting the greatest cleaning difficulty (World Health 
Organization, 2007).
Thus, an abridgement of the validation of cleaning 
processes is accepted and consists of considering critical 
scenarios or worst cases among the products or processes 
that represent a similar group. In this case, the worst 
case will represent the cleaning of all equipment in the 
production line, under the assumption that, after approval 
and cleaning validation of the worst case, the processes 
used for other products will be considered validated as 
well.
Studies of worst cases in cleaning validation are 
rare. Some have been reported by Cleaning Validation 
Technologies (2001a, b, 2004), who presented interesting 
discussions of strategies for grouping products for cleaning 
validation and their advantages and disadvantages. 
The purpose of the present study was to develop a 
strategy for worst case selection for cleaning validation 
of equipment used in radiopharmaceutical manufacture at 
the Nuclear and Energy Research Institute of the National 
Commission of Nuclear Energy (IPEN-CNEN/São Paulo), 
in particular of LRs for labeling with technetium (99mTc), 
with the aim of reducing the number of cleaning validation 
possibilities. Only the production of nonradioactive 
components was considered.
MATERIAL AND METHODS
The calculation of a worst case index (WCI) was 
based on drug solubility, difficulty of equipment cleaning, 
and occupancy of products in the production line.
Solubility factor fS
Solubility data for the drug substances used in 
the preparation of LRs were obtained mainly from 
chemical product information sheets, certificates of 
analysis containing specifications issued by the suppliers, 
in databases containing information about chemical 
products (Chemical Book, 2015; Chemspider, 2015; 
Pubchem, 2015), Material Safety Data Sheets (MSDS), 
and Merck Index (1996). For some drug substances, the 
information was not available as a number but sometimes 
as a solubility expression. The numbers and the solubility 
expressions were normalized based on the descriptive 
terms for solubility and numerical ranges defined in the 
Brazilian Pharmacopoeia (Brasil, 2010b). All numerical 
solubility data were converted to parts per million (ppm). 
Using a presumed classification for the different ranges 
of solubility, a table was created to assign a score, the 
solubility factor fS, which was used in the calculation of 
WCI.
Table I details the scores assigned to the solubility 
factor fS.
A higher fS was assigned to drugs with higher 
solubility and a lower fS to drugs with lower solubility. 
Cleaning difficulty factor fD
The factor fD was obtained from responses given 
during interviews with operators of the LR production 
area responsible for routine cleaning of equipment. A 
questionnaire with three response options was presented 
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to operators. A score based on cleaning difficulty was 
established, considering the production of all LR. Table 
II presents the scores assigned to the cleaning difficulty 
factor fD.
The score assigned to the fD and presented in Table 
II is related to the difficulty of cleaning the equipment 
and is directly proportional to the difficulty in performing 
cleaning procedures for a given product (LR).
The response of the most experienced operator was 
considered most important when a disagreement between 
responses was obtained.
Occupation factor fO
To calculate fO, typical data of lot numbers per year 
for each LR were obtained. The range of lot numbers was 
divided into five subranges and each received a score. The 
score corresponded to the occupation factor fO as described 
in Table III.
The factor fO is related to the use period of the 
production area by each LR. The selection of this factor 
was based on the number of cleaning procedures that 
need to be performed for each LR and in the probability 
of cross-contamination. There is a greater chance for a 
product manufactured more often to contaminate others 
than for products that are manufactured less frequently.
After the factors were defined, the WCI was 
calculated using equation 1.
  (Eq. 1)
where: fS is the solubility factor of the drug in water 
expressed in ppm, fD is a factor that represents the difficulty 
of cleaning the equipment, and fO is the occupancy factor 
of the production line by a given drug 
RESULTS AND DISCUSSION
The determination of the worst case for cleaning 
validation of the equipment used in the LR production area 
in IPEN was based on the work of Alencar, Clementino, 
and Neto (2006), which employed the strategy of selecting 
the worst case product in the Laboratório Farmacêutico 
do Estado de Pernambuco S/A-LAFEPE. It established 
an index incorporating information on toxicity, solubility, 
and difficulty of cleaning as well as the occupancy rate of 
each product in each unit of the laboratory. The factors 
were combined in a numerical index called Worst Case 
Index (WCI), and the magnitude of the index allowed the 
selection of the worst case product that should be used in 
cleaning validation. In the present study, toxicity data were 
not found for most of drug substances, so this parameter 
was not considered. The drugs used in the present study 
represented all the manufactured products in the LR 
production area at IPEN.
Usually, drug substance solubility’s is expressed 
as functions of the amount of solvent required for 
TABLE I - Solubility factor fS
Descriptive term Solubility (S) in water (ppm) Classification Score fS
Highly soluble S > 1,000,000
High solubility 3Easily soluble 100,000 < S < 1,000,000
Soluble 33,000 < S < 100,000
Sparingly soluble 10,000 < S < 33,000
Moderate solubility 2
Slightly soluble 1,000 < S < 10,000
Very slightly soluble 100 < S < 1,000
Low solubility 1
Practically insoluble or insoluble S < 100
Source: adapted from Brasil (2010b).
  
TABLE II - Cleaning difficulty factor fD
Score - fD Cleaning difficulty
3 Hard to clean
2 Moderately difficult to clean
1 Easy to clean
TABLE III - Occupation factor fO
Score - fO Quantity (lots/year)
5 More than 50 lots
4 31–50 lots
3 21–30 lots
2 11–20 lots
1 Up to 10 lots
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solubilization of a given mass of solute, and for many 
compounds, solubility data are listed in pharmacopeias. 
However, the Brazilian Pharmacopoeia (Brasil, 2010b) 
and USP 38 (United States Pharmacopeia, 2015) lacked 
solubility information for the drug substances used in the 
production of LR for labeling with 99mTc. Accordingly, 
other sources were consulted, as described in Methods. 
Drug solubility has a high influence on the cleaning 
validation of equipment, given that the lower the water 
solubility, the higher the adhesion to the equipment and 
consequently, the more difficult the cleaning procedures, 
resulting in a higher contribution to the WCI index.
Some studies of methods for validation of equipment 
cleaning have been described (Alencar et al., 2004, 2006a; 
Andrade, 2012; Bago, 2010). Many industries seek a 
common denominator for grouping similar products, 
and by this process, they aim to turn a complex situation 
into a manageable project. Each industry has developed 
its own criteria and methodology for the selection of the 
worst case product (Agalloco, 1992). In the present study, 
solubility data, the difficulty of cleaning equipment, and 
the occupancy of the production line by the product were 
all used to determine the worst case for the cleaning 
validation of equipment used in the manufacture of 
radiopharmaceuticals-LR.
Solubility in water and references used in the 
calculation for their expression in ppm are shown in 
Table IV.
Table V shows lot numbers of LR manufactured in 
2013 at IPEN/CNEN-SP.
The values of the factors fS, fD, and fO and the calculated 
value of the WCI index for each radiopharmaceutical are 
shown in Table VI. The WCI values of the products are 
shown in descending order.
The products PUL-TEC and MIBI-TEC showed the 
highest WCI index, with the same value of 3.0.
The WCI index of PUL-TEC can be attributed to its 
high solubility as well as difficulty in cleaning, in addition 
TABLE IV - Solubility data for LR manufactured at IPEN-CNEN/SP
Product - LR Drug substance Water solubility 
(per reference)
Water solubility in ppm 
(calculated)
Reference
CIS-TEC ethylenedicysteine 4.712 × 105 mg/L 471,200 Chemspider
DEX-500-TEC dextran 500 ***Soluble Pharmacosmos
DEX-70-TEC dextran 70 ***Soluble Pharmacosmos
DISI-TEC disophenin 52.751 mg/L 52,751 Chemspider
DMSA-TEC succimer 2.88 × 105 mg/mL 288,000,000 Pubchem
DTPA-TEC pentetic acid 4.8 g/L 4,800 Merck Index
ECD-TEC
ethylenedicysteine 
diethyl ester 
dihydrochloride
***Soluble H2O/HCl ABX
FITA-TEC phytic acid Soluble Merck Index; Chemspider
MDP-TEC medronic acid 50 mg/mL 50,000 Sigma-Aldrich
MIBI-TEC copper tetraMIBI 
tetrafluoroborate
25 g/L 25,000 Lantheus Medical Imaging
PIRO-TEC sodium pyrophosphate decahydrate
8.14 g/100 mL 
Soluble 81,400 Merck Index; Chemspider
PUL-TEC *human albumin **50 mg/mL 50,000 **Sigma-Aldrich human albumin 30% solution
*SAH-TEC *human albumin **50 mg/mL 50,000 **Sigma-Aldrich human albumin 30% solution
TIN-TEC tin(II) fluoride Soluble 106 mg/L 1,000,000 Merck Index; Chemspider
* During the manufacturing of LR SAH-TEC and PUL-TEC, the drug product Human Albumin 20% solution (Grifols) is used as 
the active ingredient. Its solubility is not available in the Certificate of Analysis issued by the manufacturer. Solubility data were 
not found in any other source. ** Solubility of Human Albumin 30% Solution (Sigma-Aldrich) was used. *** A numeric reference 
value of solubility was not found for the drugs ethylenedicysteine, diethyl ester dihydrochloride, dextran 70, and dextran 500.
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to an intermediate occupancy rate (> 20 lots), according 
to the operator’s experience.
A few considerations apply to the WCI index of 
PUL-TEC: aspects of the production process and albumin 
characteristics. These may explain the discrepancy 
between the high solubility attributed to the drug and 
the high cleaning difficulty reported by the operators. 
Albumin is the most abundant plasma protein and is a 
small molecule relative to other proteins. It is formed 
as a 584 amino acid chain with a molecular weight of 
approximately 69,000 Daltons (Cuppari, 2004).
Proteins are complex macromolecules formed of 
amino acid polymers and have four different structure levels: 
primary, secondary, tertiary, and quaternary. Although the 
sequence of amino acids corresponds to the primary protein 
structure, the chemical and biological properties are highly 
dependent on the three-dimensional or tertiary structure 
(Food Ingredients Brasil, 2012; Particle Sciences, 2009). 
Proteins can be classified by solubility, composition, 
function, shape, and size. Classification based on solubility 
and composition divides proteins into three main groups: 
simple, conjugated, and derived proteins. After hydrolysis, 
simple proteins yield only amino acids. and they coagulate 
upon heat treatment. Albumins are classified as simple 
proteins and the main property differentiating them from all 
other proteins is water solubility (Food Ingredients Brasil, 
2012). Masuelli (2013) reported that albumin solubility is 
due to its high total electric charge and consequent strong 
hydrophilic ability. At pH close to neutrality, albumins are 
highly soluble in water: to 35% by weight in diluted saline 
solutions and to 50% by weight in pure water (Masuelli, 
2013).
Several agents can change protein structure: 
for example, heating. This phenomenon is known as 
protein denaturation and consists of the breakdown of 
protein secondary and tertiary structures. As a result of 
denaturation, there is a change in the protein form, with a 
breaking of hydrogen bonds (responsible for the stability 
of protein conformation) and a consequent unraveling of 
peptide chains, which stretches them. This event causes a 
decrease in solubility and an increase in viscosity (Food 
Ingredients Brasil, 2012). During the manufacturing 
process of PUL-TEC, human albumin is heated to 100 °C, 
leading to denaturation, decreased solubility, and increased 
viscosity. This process explains the discrepancies in the 
information obtained for the calculation of the WCI index 
for PUL-TEC. Another factor that contributes to the 
solubility decrease and the viscosity increase is the use 
of sodium hydroxide (NaOH), a strong base, during the 
PUL-TEC manufacturing process.
For the product MIBI-TEC, which also showed an 
intermediate occupancy rate, the intermediate cleaning 
difficulty and particularly the moderate solubility 
influenced the calculated WCI index of 3.0.
TABLE V - Lot numbers of LR manufactured at IPEN-CNEN/
São Paulo in 2013
Product Drug substance Lot numbers
CIS-TEC ethylenedicysteine 12
DEX-500-TEC dextran 500 11
DEX-70-TEC dextran 70 11
DISI-TEC disophenin 11
DMSA-TEC succimer 17
DTPA-TEC pentetic acid 23
ECD-TEC ethylenedicysteine 
diethyl ester dihydrochloride
15
FITA-TEC phytic acid 15
MDP-TEC medronic acid 53
MIBI-TEC copper tetraMIBI tetrafluoroborate 25
PIRO-TEC sodium pyrophosphate 
decahydrate
19
PUL-TEC human albumin 26
SAH-TEC human albumin 6
TIN-TEC tin(II) fluoride 9
TABLE VI - Values of factors fO, fD, fS and WCI calculation for 
each LR manufactured at IPEN-CNEN/São Paulo
Product fO fD fS WCI
PUL-TEC 3 3 3* 3
MIBI-TEC 3 2 2 3
MDP-TEC 5 1 2 2.5
DISI-TEC 2 1 1 2.0
DEX-500-TEC 2 3 3 2.0
DTPA-TEC 3 1 2 1.5
DEX-70-TEC 2 2 3 1.33
DMSA-TEC 2 2 3 1.33
FITA-TEC 2 2 3 1.33
SAH-TEC 1 2 3* 0.66
CIS-TEC 2 1 3 0.66
PIRO-TEC 2 1 3 0.66
ECD-TEC 2 1 3 0.66
TIN-TEC 1 1 3 0.33
* The solubility factor fS used in the WCI calculation was 
obtained with Human Albumin 30% Solution (Sigma-Aldrich) 
data.
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The product MDP-TEC showed a WCI (2.5) similar 
to those of MIBI-TEC and PUL-TEC, with moderate 
solubility, ease of cleaning, and high occupancy factor 
(highest among the LR), as reflected in the WCI. 
The WCI index calculated for DISI-TEC and 
DEX-500-TEC was the same (2.0), and both presented 
the same relatively low occupancy factor (11 lots). For 
DISI-TEC, easy cleaning and low solubility influenced 
the WCI, whereas the high solubility of DEX-500-TEC 
was highly influential in the WCI calculation. Even 
though the cleaning operators rated DEX-500-TEC as a 
product causing difficulty in cleaning, the Pharmacosmos 
company specializing in dextran synthesis points out 
that dextran fractions are highly soluble in water and 
electrolyte solutions and form clear and stable solutions 
(Pharmacosmos, 2015). They may form turbid solutions 
(during rest) when concentrated solutions of dextran 
fractions of low molecular weight (5,000 and 10,000) are 
used.
The products DEX-70-TEC, DMSA-TEC, and 
FITA-TEC showed the same WCI value (1.33), close to the 
result obtained for DTPA-TEC. High solubility, moderate 
cleaning difficulty, and relatively low occupancy factor 
influenced the calculation.
The products SAH-TEC, CIS-TEC, PIRO-TEC, 
and ECD-TEC showed the same WCI index (0.66), 
distinct from that of PUL-TEC and MIBI-TEC. The high 
solubility of these four products and the low occupancy 
rate (the lowest among all products) of the first product 
were decisive factors in WCI determination. The product 
with the lowest WCI was TIN-TEC. 
With the identification of products with the highest 
WCI indexes, the Radiopharmacy Center of IPEN-CNEN/
SP now has, in the products PUL-TEC and MIBI-TEC, 
a potential reference for the validation of the cleaning 
procedures of LR production equipment.
CONCLUSION
The starting point for a cleaning validation is an 
analysis of the critical situations or worst cases among the 
products or production processes that represent a similar 
group. That are guidelines showing it is preferable to use 
toxicological data. In the case of radiopharmaceuticals, 
the acquisition of these data was challenging because 
the active ingredient is either a radioactive material or a 
material that is not commonly used in the conventional 
pharmaceutical industry, so that such data are largely 
unavailable.
One of the main features of cleaning validation 
involves studies of the pharmaceutical previously 
produced and the product subsequently manufactured 
in the cleaned equipment. Considering that the LR 
radiopharmaceutical production area produces 14 
LRs, there are several possible product sequences to 
be evaluated. The present study determined the two 
worst cases among 14 LR for cleaning validation of the 
production equipment, representing an 85.7% reduction 
in the number of cleaning validation procedures. 
The results obtained in this study showed that the 
worst case approach for cleaning validation, based on the 
calculation of an index that accounts for critical process 
parameters, is a simple and effective way to reduce 
the complexity and time requirement of the validation 
process, besides providing a way to reduce the cost of 
these activities.
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